Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma

Journal of Nuclear Medicine

Volumn 39, Issue 6, 1998, Pages 1016-1020

  Higashi, Kotaro ^a   Ueda, Yoshimichi ^b   Seki, Hiroyasu ^b   Yuasa, Kokichi ^b   Oguchi, Manabu ^b   Noguchi, Tetsuhiko ^b   Taniguchi, Mitsuru ^b   Tonami, Hisao ^b   Okimura, Tetsuro ^b   Yamamoto, Itaru ^b  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

^b NONE

Author keywords

Bronchioloalveolar lung carcinoma; Fluorine 18 fluorodeoxyglucose; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CELL; CELL DIFFERENTIATION; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DRUG UPTAKE; FEMALE; GLUCOSE METABOLISM; HUMAN; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; THORACOTOMY;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; AGED; AGED, 80 AND OVER; FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0031863737     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospected study. J Nucl Med 1990;31:1927-1933.
2. 18F]-fluoro-2-deoxy-D-glucose. Radiology 1992;184: 441-444.
3. 18F-fluorodeoxyglucose PET scanning. Radiology 1993;188:487-490.
4. 18F]fluorodeoxyglucose. Ann Thorac Surg 1994;58:698-703.
5. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick NP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Chest 1993;104:997-1002.
6. Wahl RL. Positron emission tomography: applications in oncology. In: Murray IPC, Ell PJ, ed. Nuclear medicine in clinical diagnosis and treatment, vol. 2. New York: Churchill Livingstone; 1994:801-820.
7. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996;37:943-948.
8. Jang HJ, Lee KS, Kwon OJ, Rhee CH, Shim YM, Han J. Bronchioloalveolar carcinoma: focal area of ground-glass attenuation at thin-section CT as an early sign. Radiology 1996;199:485-488.
9. Clayton F. The spectrum and significance of bronchioloalveolar carcinomas. Pathl Annu 1988;23:361-394.
10. Heikkila L, Mattila P, Harjiula A, Sumalainen RJ, Mattila S. Tumor growth rate and its relationship to prognosis in bronchiolo-alveolar and pulmonary adenocarcinoma. Ann Chir Gynaecol 1985;74:210-214.
11. 18F-fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-1329.
12. Minn H, Joensuu H, Ahonen A. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988;61:1776-1781.
13. Okada J, Yoshikawa K, Itami M, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 1992;33:325-329.
14. Duhaylongsod FG, Lowe VJ, Patz EF, et al. Lung tumor growth correlations with glucose metabolism measured by fluoride-18-fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348-1362.
15. Rodriguez M, Rehn S, Ahlstom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790-1796.
16. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257-261.
17. Higashi K, Nishikawa T, Ueda Y, et al. Association of FDG uptake with proliferating cell nuclear antigen, Ki-67 and DNA ploidy pattern in non-small cell lung carcinoma [Abstract]. J Nucl Med 1996;37:64.
18. World Health Organization. Histological typing of lung tumors, 2nd ed. Geneva: World Health Organization; 1981:25-26.
19. Barsky S, Cameron R, Osann KE, Tomita D, Holmes C. Rising incidence of BAC and its unique clinicopathologic features. Cancer 1994;73:1163-1170.
20. Auerbach O, Garfinkel L. The changing pattern of lung carcinoma. Cancer 1991;68: 1973-1977.
21. Kitamura H, Kameda Y, Nakamura N, et al. Proliferative potential and p53 overexpression in precursor and early stage lesions of BAC. Am J pathol 1995;147:876-887.
22. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Cancer 1995;75:2844-2852.
23. Dalquen P, Sauter G, Torhorst J, et al. Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma. J Pathol 1996;178:53-58.
24. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993;34:414-419.
25. Keyes JW. SUV: standard uptake or silly useless value ? J Nucl Med 1995;36:1836-1839.
26. Kubota K, Matsuzawa T, Ito M, et al. Lung tumor imaging by positron emission tomography using carbon-11-L-methionine. J Nucl Med 1985;26:37-42.
27. Rusch VW, Reuter VE, Kris MG, et al. Ras oncogene point mutation: an infrequent event in bronchiloalveolar cancer. J Thorac Cardiovasc Surg 1992;104:1465-1469.
28. 18F-fluorodeoxyglucose uptake by proliferating and prenecrotic cancer cells in vivo: a microautoradiographic study. J Nucl Med 1994;35:1067-1075.
29. Radriguez M, Rehn S, Ahlstrom H, Sundstrom C, Glimelius B. Predicting malignancy grade with PET in non-Hodgkin's lymphoma. J Nucl Med 1995;36:1790-1796.
30. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257-261.